206 related articles for article (PubMed ID: 19093182)
1. Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer.
Tamura S; Miki H; Okada K; Miyake T; Yoshimura M; Suzuki R; Nakahira S; Nakata K; Okamura S; Sugimoto K; Takatsuka Y
Int J Clin Oncol; 2008 Dec; 13(6):536-40. PubMed ID: 19093182
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer.
Tamura S; Miki H; Nakata K; Takiuchi D; Okada K; Nakahira S; Okamura S; Sugimoto K; Tomita N; Takatsuka Y
Gastric Cancer; 2007; 10(4):251-5. PubMed ID: 18095081
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer.
Tamura S; Miki H; Okada K; Takeno A; Uji K; Yoshida A; Suzuki R; Nakahira S; Egawa C; Nakata K; Okamura S; Sugimoto K; Takatsuka Y
Gastric Cancer; 2010 Jun; 13(2):101-8. PubMed ID: 20602197
[TBL] [Abstract][Full Text] [Related]
4. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Kitayama J; Ishigami H; Yamaguchi H; Yamashita H; Emoto S; Kaisaki S; Watanabe T
Ann Surg Oncol; 2014 Feb; 21(2):539-46. PubMed ID: 23975319
[TBL] [Abstract][Full Text] [Related]
5. [Pilot study of neo-adjuvant chemotherapy involving intraperitoneal administration of paclitaxel and oral S-1 for patients with T3 gastric cancer].
Tamura S; Miki H; Okada K; Yoshimura M; Uji K; Yoshida A; Suzuki R; Nakahira S; Egawa C; Nakata K; Okamura S; Sugimoto K; Takatsuka Y
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2024-6. PubMed ID: 19106511
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial.
Kodera Y; Takahashi N; Yoshikawa T; Takiguchi N; Fujitani K; Ito Y; Miyamoto K; Takayama O; Imano M; Kobayashi D; Miyashita Y; Morita S; Sakamoto J
Gastric Cancer; 2017 Jan; 20(1):190-199. PubMed ID: 26879545
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
Yamaguchi H; Kitayama J; Ishigami H; Emoto S; Yamashita H; Watanabe T
Cancer; 2013 Sep; 119(18):3354-8. PubMed ID: 23798046
[TBL] [Abstract][Full Text] [Related]
8. [A case of gastric cancer with peritoneal dissemination which showed the intraperitoneal CR by administrating TS-1 orally and paclitaxel intraperitoneally].
Miki H; Tamura S; Wada H; Kozuma Y; Kittaka N; Kim T; Takiuchi D; Aihara T; Sugimoto K; Fukunaga M; Ozato H; Tomita N; Takatsuka Y
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1661-4. PubMed ID: 14619488
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Ishigami H; Kitayama J; Kaisaki S; Hidemura A; Kato M; Otani K; Kamei T; Soma D; Miyato H; Yamashita H; Nagawa H
Ann Oncol; 2010 Jan; 21(1):67-70. PubMed ID: 19605503
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
Shinkai M; Imano M; Chiba Y; Hiraki Y; Kato H; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
Anticancer Res; 2018 Oct; 38(10):5969-5974. PubMed ID: 30275227
[TBL] [Abstract][Full Text] [Related]
11. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y
Oncology; 2020; 98(1):48-52. PubMed ID: 31487733
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination.
Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
J Surg Oncol; 2012 Jan; 105(1):38-42. PubMed ID: 21882194
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
Shinkai M; Imano M; Chiba Y; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
Anticancer Res; 2018 Oct; 38(10):5975-5981. PubMed ID: 30275228
[TBL] [Abstract][Full Text] [Related]
14. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
Ishigami H; Yamaguchi H; Yamashita H; Asakage M; Kitayama J
Gastric Cancer; 2017 Mar; 20(Suppl 1):128-134. PubMed ID: 28028665
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
[TBL] [Abstract][Full Text] [Related]
16. A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis.
Imano M; Peng YF; Itoh T; Nishikawa M; Satou T; Yasuda A; Inoue K; Kato H; Shinkai M; Tsubaki M; Yasuda T; Imamoto H; Nishida S; Furukawa H; Takeyama Y; Okuno K; Shiozaki H
Anticancer Res; 2012 Sep; 32(9):4071-5. PubMed ID: 22993363
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
Shi M; Yang Z; Lu S; Liu W; Ni Z; Yao X; Hua Z; Feng R; Zheng Y; Wang Z; Sah BK; Chen M; Zhu Z; He C; Li C; Zhang J; Yan C; Yan M; Zhu Z
BMC Cancer; 2021 Dec; 21(1):1344. PubMed ID: 34922478
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis.
Yamaguchi H; Satoh Y; Ishigami H; Kurihara M; Yatomi Y; Kitayama J
Ann Surg Oncol; 2017 Oct; 24(11):3345-3352. PubMed ID: 28726078
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
[TBL] [Abstract][Full Text] [Related]
20. [A Case of Long-Term Survival of a Patient with Gastric Cancer with Peritoneal Dissemination].
Nakao K; Shitara K; Fukunari H; Yamamoto Y; Kato T; Okajima C; Hayashi T; Watanabe G
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2000-2. PubMed ID: 26805244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
